Daewon Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Daewon Pharmaceutical has a total shareholder equity of ₩282.8B and total debt of ₩161.0B, which brings its debt-to-equity ratio to 56.9%. Its total assets and total liabilities are ₩561.0B and ₩278.2B respectively. Daewon Pharmaceutical's EBIT is ₩38.6B making its interest coverage ratio 8.6. It has cash and short-term investments of ₩60.9B.
Key information
56.9%
Debt to equity ratio
₩161.03b
Debt
| Interest coverage ratio | 8.6x |
| Cash | ₩60.86b |
| Equity | ₩282.78b |
| Total liabilities | ₩278.22b |
| Total assets | ₩561.00b |
Recent financial health updates
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26
Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10
Recent updates
There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22Financial Position Analysis
Short Term Liabilities: A003220's short term assets (₩257.3B) exceed its short term liabilities (₩218.3B).
Long Term Liabilities: A003220's short term assets (₩257.3B) exceed its long term liabilities (₩59.9B).
Debt to Equity History and Analysis
Debt Level: A003220's net debt to equity ratio (35.4%) is considered satisfactory.
Reducing Debt: A003220's debt to equity ratio has increased from 19.6% to 56.9% over the past 5 years.
Debt Coverage: A003220's debt is well covered by operating cash flow (21.9%).
Interest Coverage: A003220's interest payments on its debt are well covered by EBIT (8.6x coverage).